Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 70476-82-3] Mitoxantronedihydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-13502A
Brand:	MCE
CAS:	70476-82-3

Overview

MDL	MFCD00242943
Molecular Weight	517.40
Molecular Formula	C22H30Cl2N4O6
SMILES	O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O.[H]Cl.[H]Cl

For research use only. We do not sell to patients.

14 Publications Citing Use of MCE

[1]Cancers. 2020 Aug 4;12(8):2169.
[2]Cell Oncol. 2020 Dec;43(6):1099-1116.
[3]Acta Pharmacol Sin. 2022 Aug 31.
[4]Drug Deliv. 2022 Dec;29(1):2561-2578.
[5]Int J Biol Sci. 2022 Mar 21;18(6):2568-2582.
[6]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
[7]Exp Cell Res. 2020 Aug 1;393(1):112054.
[8]BMC Cancer. 2021 Oct 13;21(1):1101.
[9]Med Oncol. 2020 Nov 19;37(12):116.
[10]J Pharm Pharmacol. 2022 Jan 5;74(1):41-56.
[11]J Pharm Pharmacol. 23 November 2021.
[12]Pharm Dev Technol. 2021 Apr 30;1-9.
[13]bioRxiv. 2023 Jan 13.
[14]Research Square Print. November 28th, 2022.

Summary

Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C ( PKC ) activity with an IC ₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity ^[1] ^[2] ^[3] ^[4] . Mitoxantrone dihydrochloride also has anti- orthopoxvirus activity with EC ₅₀ s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively ^[5] .

IC50 & Target

PKC

8.5 μM (IC ₅₀ )

Topoisomerase II

In Vitro

Mitoxantrone dihydrochloride inhibits PKC in a competitive manner with respect to histone H1, and its K _i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP ^[1] .
Mitoxantrone dihydrochloride (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone dihydrochloride induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone dihydrochloride is due to induction of apoptosis ^[2] .
Mitoxantrone dihydrochloride shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC ₅₀ values of 18 and 196 nM, respectively ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mitoxantrone dihydrochloride (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia ^[4] .
Mitoxantrone dihydrochloride (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02724163	University of Birmingham\|Assistance Publique - Hôpitaux de Paris\|Cancer Research UK\|National Cancer Institute, France\|Pfizer	Acute Myeloid Leukaemia	April 2016	Phase 3
NCT00452387	Accelerated Community Oncology Research Network\|Bayer	Metastatic Prostate Cancer	May 2007	Phase 2
NCT00002565	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Lymphoma	May 25, 1994	Phase 3
NCT00906945	Washington University School of Medicine	Leukemia, Myeloid, Acute	February 2011	Phase 1\|Phase 2
NCT00003957	Fox Chase Cancer Center\|National Cancer Institute (NCI)	Lymphoma	December 1998	Phase 2
NCT00002701	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto\|National Cancer Institute (NCI)	Leukemia	October 1995	Phase 3
NCT00003183	Hope Cancer Institute, Inc.\|National Cancer Institute (NCI)	Prostate Cancer	March 1997	Phase 1\|Phase 2
NCT04509466	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Extranodal NK+T-cell Lymphoma, Nasal Type	August 15, 2020	Phase 1\|Phase 2
NCT00002259	Lederle Laboratories\|NIH AIDS Clinical Trials Information Service	Sarcoma, Kaposi\|HIV Infections		Phase 2
NCT00002766	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	March 1996	Phase 3
NCT00304291	State University of New York at Buffalo\|EMD Serono	Neuromyelitis Optica\|Myelitis, Transverse\|Demyelinating Autoimmune Diseases, CNS\|Autoimmune Diseases of the Nervous System	August 2001	Phase 4
NCT03860844	Sanofi	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	August 6, 2019	Phase 2
NCT00002544	Arbeitsgemeinschaft fur Internistische Onkologie\|National Cancer Institute (NCI)	Breast Cancer	May 1993	Phase 3
NCT01371981	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Leukemia Cutis\|Myeloid Neoplasm\|Myeloid Sarcoma	June 20, 2011	Phase 3
NCT00372593	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 2006	Phase 3
NCT00079105	Newcastle-upon-Tyne Hospitals NHS Trust	Lymphoma	January 2004	Phase 2
NCT00407966	National Cancer Institute (NCI)	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	October 2006	Phase 2
NCT02597387	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Relapsed DLBCL and PT+NKCLs	August 2015	Phase 2
NCT01403415	National Cancer Institute (NCI)	Childhood B Acute Lymphoblastic Leukemia\|Childhood T Acute Lymphoblastic Leukemia\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Lymphoblastic Lymphoma	September 2011	Phase 1
NCT01594918	Rahul Aggarwal\|Sanofi\|University of California, San Francisco	Metastatic Castration-resistant Prostate Cancer	June 2012	Phase 1
NCT03735446	Dana-Farber Cancer Institute\|Eli Lilly and Company	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	January 18, 2019	Phase 1
NCT00842595	French Innovative Leukemia Organisation	Diffuse Large B-Cell Lymphoma	December 2003	Phase 2
NCT00004071	Pfizer	Prostate Cancer	August 1999	Phase 2\|Phase 3
NCT00477087	Stanford University\|Bayer	Prostatic Neoplasms	July 2006	Phase 2
NCT01768897	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Recurrent Adult Acute Myeloid Leukemia	January 2013	Phase 1
NCT00203073	Teva Branded Pharmaceutical Products R&D, Inc.	Relapsing Remitting Multiple Sclerosis	June 2003	Phase 2
NCT03776279	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Relapsed or Refractory Peripheral T-cell and NK+T-cell Lymphoma	April 2, 2018	Phase 2
NCT00002819	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group\|Southwest Oncology Group\|Cancer and Leukemia Group B\|GOG Foundation	Ovarian Cancer	November 1996	Phase 3
NCT00124566	Eisai Inc.	Prostate Cancer	June 2004	Phase 2
NCT02101853	National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia	December 8, 2014	Phase 3
NCT00005867	Lymphoma Trials Office\|National Cancer Institute (NCI)	Lymphoma	January 1998	Phase 3
NCT00408278	PETHEMA Foundation	Acute Promyelocytic Leukemia	July 2005	Phase 4
NCT05330377	Ayman H Qasrawi\|Astellas Pharma Inc\|University of Kentucky	Acute Myeloid Leukemia	March 2023	Phase 1
NCT01842672	New York Medical College	Acute Lymphoblastic Leukemia\|Acute Myelogenous Leukemia\|Lymphoblastic Lymphoma\|Diffuse Large B-cell Lymphoma\|Burkitt Lymphoma+Leukemia	March 2013	Phase 1\|Phase 2
NCT00337246	Cancer Research UK\|National Cancer Institute (NCI)	Leukemia	July 2005	Phase 2
NCT00006114	GERCOR - Multidisciplinary Oncology Cooperative Group\|National Cancer Institute (NCI)	Prostate Cancer	May 1999	Phase 2
NCT04797767	University of Washington\|AbbVie	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Mixed Phenotype Acute Leukemia\|Myeloid Neoplasm\|Relapsed Acute Biphenotypic Leukemia\|Relapsed Acute Myeloid Leukemia\|Relapsed Mixed Phenotype Acute Leukemia\|Relapsed Myeloid Neoplasm\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Mixed Phenotype Acute Leukemia\|Refractory Myeloid Neoplasm	February 4, 2022	Phase 1
NCT02583893	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	October 7, 2015	Phase 2
NCT04927481	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Breast Cancer	June 11, 2021	Phase 2
NCT03983824	National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	October 4, 2019	Phase 1
NCT05299164	Institute of Hematology & Blood Diseases Hospital\|CSPC Ouyi Pharmaceutical Co., Ltd.	Non Hodgkin Lymphoma	May 15, 2022	Phase 1
NCT05089461	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Malignant Tumor	March 7, 2022	Phase 2
NCT04331743	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Hepatocellular Carcinoma	June 5, 2021	Phase 1
NCT00016016	National Cancer Institute (NCI)	Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 2001	Phase 1\|Phase 2
NCT00002003	Lederle Laboratories\|NIH AIDS Clinical Trials Information Service	Lymphoma, Non-Hodgkin\|HIV Infections		Phase 2
NCT00458848	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	October 2004	Phase 2
NCT00003003	Dartmouth-Hitchcock Medical Center\|National Cancer Institute (NCI)	Leukemia	September 1996	Phase 1
NCT00053131	Roswell Park Cancer Institute	Leukemia	January 1999	Phase 2
NCT00047021	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	November 2001	Phase 2
NCT02848183	Samsung Medical Center	Pediatric Acute Myeloid Leukemia	January 2016	Phase 2
NCT01801046	University of Southern California\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myeloid Leukemia in Remission\|Childhood Acute Myelomonocytic Leukemia (M4)\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	March 6, 2013	Phase 1
NCT00770848	Amgen	Cancer\|Castrate-Resistant Prostate Cancer\|Mestastatic Prostate Cancer\|Prostate Cancer	November 2008	Phase 1\|Phase 2
NCT00006122	European Organisation for Research and Treatment of Cancer - EORTC	Leukemia	June 2000	Phase 2
NCT02070458	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	October 8, 2014	Phase 1
NCT00002912	National Cancer Institute (NCI)	Leukemia	January 1997	Phase 1
NCT00967057	Children´s Cancer and Leukaemia Group\|National Cancer Institute (NCI)	Leukemia	October 2002	Phase 3
NCT00017563	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Prostate Cancer	September 2000	Phase 2
NCT05345938	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Relapsed or Refractory Acute Myeloid Leukemia (AML)	May 30, 2022	Phase 1\|Phase 2
NCT00609739	Masonic Cancer Center, University of Minnesota	Leukemia	June 1999	Phase 1\|Phase 2
NCT00556127	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie	Diffuse Large B-Cell Lymphoma\|POOR PROGNOSIS	June 2002	Phase 2
NCT00003436	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	July 1998	Phase 3
NCT00002700	European Organisation for Research and Treatment of Cancer - EORTC\|Acute Leukemia French Association	Leukemia\|Lymphoma	August 1995	Phase 3
NCT01127009	Case Comprehensive Cancer Center	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	July 2010	Phase 1
NCT00006250	Lymphoma Trials Office\|National Cancer Institute (NCI)	Lymphoma	May 2000	Phase 3
NCT04718402	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Gastric Carcinoma	March 30, 2021	Phase 1
NCT00010075	GERCOR - Multidisciplinary Oncology Cooperative Group\|National Cancer Institute (NCI)	Breast Cancer	January 2000	Phase 2
NCT00028899	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	July 2002	Phase 1
NCT00169208	Lymphoma Study Association	Follicular Lymphoma	April 2001	Phase 2
NCT02518750	St. Jude Children´s Research Hospital\|Novartis Pharmaceuticals\|Spectrum Pharmaceuticals, Inc	Acute Lymphoblastic Leukemia\|Lymphoma, Non-Hodgkin´s\|Leukemia, T-Cell\|Leukemia, B-Cell	November 23, 2016	Phase 2
NCT00002576	Cancer Research Campaign Clinical Trials Centre\|National Cancer Institute (NCI)	Lymphoma	November 1992	Phase 3
NCT00002498	Leiden University Medical Center\|National Cancer Institute (NCI)	Breast Cancer	July 1992	Phase 2
NCT05441761	Peking Union Medical College Hospital\|CSPC Ouyi Pharmaceutical Co., Ltd.	Treatment\|Peripheral T-cell Lymphoma	May 1, 2022	Phase 1\|Phase 2
NCT00058084	National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer\|Stage IV Prostate Cancer	March 2003	Phase 2
NCT00004001	Southwest Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|North Central Cancer Treatment Group	Prostate Cancer	October 1999	Phase 3
NCT02728050	University of Washington\|National Cancer Institute (NCI)\|Bayer	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm	December 1, 2016	Phase 1\|Phase 2
NCT00627354	Groupe D´Etude des Tumeurs Uro-Genitales\|National Cancer Institute (NCI)	Prostate Cancer	September 2006	Phase 2
NCT01027923	Washington University School of Medicine	Leukemia, Myeloid, Acute	May 2010	Phase 1
NCT04902027	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Recurrent Head and Neck Cancer\|Metastatic Head and Neck Cancer	July 1, 2021	Phase 1
NCT03258320	Shanghai Jiao Tong University School of Medicine\|Fudan University\|Qilu Hospital of Shandong University	Prostate Cancer Patients	January 2015	Phase 1
NCT02484391	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Granulocytic Sarcoma\|Recurrent Adult Acute Myeloid Leukemia	September 2015	Phase 2
NCT01729845	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia	December 20, 2012	Phase 1\|Phase 2
NCT00024492	INSYS Therapeutics Inc	Tumors	August 2001	Phase 1
NCT05313958	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Third Affiliated Hospital, Sun Yat-Sen University\|Maternal and Child Health Hospital of Foshan\|The First Affiliated Hospital of Guangzhou Medical University\|Second Xiangya Hospital of Central South University\|Jiangxi Province Children´s Hospital\|Southern Medical University, China\|The First Affiliated Hospital of Nanchang University\|Guangzhou First People´s Hospital\|First Affiliated Hospital of Shantou University Medical College	Leukemia, Monocytic, Acute\|Pediatric AML	December 1, 2021	Phase 2\|Phase 3
NCT00070174	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 2003	Phase 2
NCT00199069	Johann Wolfgang Goethe University Hospital\|Deutsche Krebshilfe e.V., Bonn (Germany)	Adult Acute Lymphocytic Leukemia	April 1993	Phase 4
NCT04548700	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Treatment-naïve\|Peripheral T Cell Lymphoma	December 24, 2020	Phase 1
NCT02632708	Institut de Recherches Internationales Servier\|Celgene Corporation\|Servier	Newly Diagnosed Acute Myeloid Leukemia (AML)\|Untreated AML\|AML Arising From Myelodysplastic Syndrome (MDS)\|AML Arising From Antecedent Hematologic Disorder (AHD)\|AML Arising After Exposure to Genotoxic Injury	December 31, 2015	Phase 1
NCT02856685	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Non-Hodgkin´s Lymphoma	August 2016	Phase 1\|Phase 2
NCT02299518	Bhavana Bhatnagar\|Karyopharm Therapeutics Inc\|Ohio State University Comprehensive Cancer Center	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	May 18, 2015	Phase 1
NCT02921061	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Mixed Phenotype Acute Leukemia\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory High Risk Myelodysplastic Syndrome\|Untreated Adult Acute Myeloid Leukemia	November 17, 2016	Phase 1\|Phase 2
NCT00385827	Centocor, Inc.	Cancer, Prostate	November 2006	Phase 2
NCT00005998	Masonic Cancer Center, University of Minnesota\|National Cancer Institute (NCI)	Lymphoma	January 2000	Phase 2
NCT02733380	Henan Cancer Hospital	Diffuse Large B-cell Lymphoma	May 2016	Phase 2
NCT00005802	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Leukemia	June 1999	Phase 1\|Phase 2
NCT00015951	University of Maryland, Baltimore\|National Cancer Institute (NCI)\|University of Maryland Greenebaum Cancer Center	Leukemia\|Myelodysplastic Syndromes	April 2001	Phase 2
NCT02535806	Children´s Mercy Hospital Kansas City\|Millennium Pharmaceuticals, Inc.	Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	July 2015	Phase 2
NCT00003080	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Ovarian Cancer	September 1996	Phase 1
NCT00002835	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Lymphoma	October 30, 1995	Phase 3
NCT01564784	Pfizer\|UCB Pharma	Acute Lymphoblastic Leukemia	August 2, 2012	Phase 3
NCT00447473	The Methodist Hospital Research Institute\|Bayer	Prostatic Neoplasms	July 2006	Phase 2
NCT03563560	Sumitomo Pharma Co., Ltd.	Acute Myeloid Leukemia	May 15, 2018	Phase 1
NCT03441048	Medical College of Wisconsin	Acute Myeloid Leukemia	May 22, 2018	Phase 1
NCT00417079	Sanofi	Neoplasms\|Prostatic Neoplasms	January 2007	Phase 3
NCT00002531	Johann Wolfgang Goethe University Hospital\|National Cancer Institute (NCI)	Leukemia	January 1993	Phase 2
NCT02937285	Rennes University Hospital	Multiple Sclerosis	November 2010	Phase 3
NCT01144403	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma	June 2010	Phase 2
NCT00003893	University Hospital Birmingham\|National Cancer Institute (NCI)	Breast Cancer	July 1998	Phase 3
NCT00004237	Royal Marsden NHS Foundation Trust\|National Cancer Institute (NCI)	Breast Cancer	October 1998	Phase 2
NCT00840684	Institut Paoli-Calmettes\|National Cancer Institute (NCI)	Leukemia	January 2009	Phase 1\|Phase 2
NCT00003405	Rush University Medical Center\|National Cancer Institute (NCI)	Leukemia	April 1998	Phase 2
NCT00526305	PETHEMA Foundation	Acute Lymphoblastic Leukemia	January 2000	Phase 4
NCT05551598	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Neuromyelitis Optica Spectrum Disorder	November 15, 2022	Phase 2
NCT02597153	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Relapsed Cutaneous T Cell Lymphom	October 2015	Phase 2
NCT00550992	Dutch Childhood Oncology Group\|BFM Germany\|CORS Monza Italy\|Associazione Italiana Ematologia Oncologia Pediatrica\|Australian and New Zealand Children´s Oncology Group\|BFM Austria\|CLCG France Belgium Portugal\|COALL Germany\|CPH, Czech republic\|DFCI consortium USA\|FRALLE France\|Hong Kong\|MD Anderson USA\|NOPHO Scandinavian countries\|PINDA, Chile\|PPLLSG Poland\|Seattle USA\|SJCRH USA\|UKCCSG United Kingdom	Leukemia	January 2006	Not Applicable
NCT00268242	The Cleveland Clinic\|National Cancer Institute (NCI)\|Duke University	Leukemia	January 2006	Phase 2
NCT02462265	Oshadi Drug Administration	Acute Myeloid Leukemia\|Lymphoid Leukemia	January 2017	Phase 2
NCT02400281	Arog Pharmaceuticals, Inc.	Acute Myeloid Leukemia	September 2015	Phase 1\|Phase 2
NCT00660036	University of Pittsburgh	Acute Myeloid Leukemia	September 2008	Phase 1
NCT01065727	Rennes University Hospital	Multiple Sclerosis	February 2010	Not Applicable
NCT01174888	Alison Walker\|Novartis\|Millennium Pharmaceuticals, Inc.\|Ohio State University Comprehensive Cancer Center	Acute Myeloid Leukemia\|Acute Myeloid Leukemia With Multilineage Dysplasia Following\|Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	August 2010	Phase 1
NCT02596373	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Recurrent or Metastatic Breast Cancer	June 2015	Phase 2
NCT01681537	Massachusetts General Hospital	Acute Myelogenous Leukemia	September 2012	Phase 1
NCT01004497	The Catholic University of Korea	Acute Lymphoblastic Leukemia	March 2010	Phase 2
NCT02687386	Dr David Ziegler\|Engeneic Pty Limited\|Sydney Children´s Hospitals Network	Solid Tumours\|CNS Tumours	February 8, 2016	Phase 1
NCT02303821	Amgen\|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator\|Innovative Therapies For Children with Cancer Consortium	Acute Lymphoblastic Leukemia (ALL)	February 16, 2015	Phase 1
NCT00416910	German CLL Study Group	Chronic Lymphocytic Leukemia	July 1999	Phase 3
NCT00683475	Eli Lilly and Company	Prostate Cancer	August 2008	Phase 2
NCT04921878	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Solid Tumors	June 2021	Phase 1
NCT00002549	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia	November 1993	Phase 3
NCT02419755	St. Jude Children´s Research Hospital	Mixed Lineage Acute Leukemia\|Acute Myeloid Leukemia\|Acute Lymphoid Leukemia	April 14, 2015	Phase 2
NCT01204710	Eli Lilly and Company	Prostate Cancer	October 2010	Phase 2
NCT04293562	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	July 20, 2020	Phase 3
NCT00795002	National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	November 2008	Phase 2
NCT01522443	Exelixis	Prostate Cancer\|Castration Resistant Prostate Cancer\|Pain\|Prostatic Neoplasms	March 2012	Phase 3
NCT00003858	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Prostate Cancer		Phase 2
NCT05100303	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)	December 2021	Phase 1\|Phase 2
NCT00100477	US Department of Veterans Affairs\|Immunex Corporation\|SmithKline Beecham\|Amgen\|VA Office of Research and Development	Non-Hodgkin´s Lymphoma\|Leukemia	August 1998	Phase 2
NCT05496894	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Relapsing Multiple Sclerosis	August 2022	Phase 2
NCT00059631	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals, Inc.\|National Cancer Institute (NCI)	Prostate Cancer	March 20, 2003	Phase 1
NCT02131688	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Malignant Lymphoma	May 2013	Phase 1
NCT02198482	University of Ulm	Acute Myeloid Leukemia (AML)\|High-risk Myelodysplastic Syndrome (MDS)	February 2016	Phase 2
NCT02573363	University of Chicago\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	October 7, 2015	Phase 1
NCT00193479	SCRI Development Innovations, LLC\|Genentech, Inc.\|Amgen	Non-Hodgkins Lymphoma	April 2003	Phase 2
NCT00182741	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Prostate Cancer	September 2004	Phase 2
NCT00002658	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Neutropenia	January 1994	Phase 3
NCT05620862	Sun Yat-sen University\|CSPC Ouyi Pharmaceutical Co., Ltd.	Lymphoma, Solid Tumors	October 25, 2022	Phase 1
NCT00003633	Herbert Irving Comprehensive Cancer Center\|National Cancer Institute (NCI)	Prostate Cancer	August 1998	Phase 1
NCT00002474	Loyola University\|National Cancer Institute (NCI)	Ovarian Cancer	February 1991	Phase 2
NCT03926624	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	November 22, 2019	Phase 3
NCT04719065	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Solid Tumor	January 13, 2021	Phase 1
NCT00510887	Duke University\|Millennium Pharmaceuticals, Inc.	Lymphoma, Follicular	January 2007	Phase 2
NCT02521493	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Down Syndrome\|Myelodysplastic Syndrome\|Myeloid Leukemia Associated With Down Syndrome\|Myeloproliferative Neoplasm	November 23, 2015	Phase 3
NCT00901927	M.D. Anderson Cancer Center\|Cephalon	Follicular Lymphoma	May 2009	Phase 2
NCT00290511	M.D. Anderson Cancer Center\|Genentech, Inc.\|Biogen	Lymphoma	June 29, 2004	Phase 2
NCT00002598	Memorial Sloan Kettering Cancer Center	Leukemia	June 1994	Phase 2
NCT00470197	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Malignant Neoplasm\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia	April 2007	Phase 1
NCT00278213	German CLL Study Group	Prolymphocytic Leukemia	September 2002	Phase 2
NCT05344742	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Solid Tumor	April 2022	Phase 1
NCT00003343	Pfizer	Prostate Cancer	March 1998	Phase 3
NCT00005847	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Prostate Cancer	January 2001	Phase 2
NCT00274807	The Cleveland Clinic\|National Cancer Institute (NCI)	Leukemia	June 2001	Phase 2
NCT00180128	Technische Universität Dresden	Leukemia, Promyelocytic, Acute	January 2000	Phase 4
NCT00656084	US Oncology Research\|Eli Lilly and Company	Relapsed or Refractory Mantle Cell Lymphoma (MCL)	December 2004	Phase 2
NCT00774046	University of Chicago	Myelodysplastic Syndrome\|Acute Myeloid Leukemia	December 2002	Phase 2
NCT00004124	Southwest Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B	Prostate Cancer	October 1999	Phase 3
NCT00744081	Johann Wolfgang Goethe University Hospital	AML	July 2004	Phase 2
NCT01184898	Sidney Kimmel Cancer Center at Thomas Jefferson University\|University of Pennsylvania\|Thomas Jefferson University	AML	July 2010	Not Applicable
NCT00546377	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2005	Phase 1\|Phase 2
NCT00004197	University of Nebraska\|National Cancer Institute (NCI)	Lymphoma	June 1999	Phase 2
NCT02626338	Arog Pharmaceuticals, Inc.	Relapsed+Refractory Acute Myeloid Leukemia (AML)	February 2016	Phase 1\|Phase 2
NCT00003032	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Breast Cancer	April 25, 1997	Phase 3
NCT04375631	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Mixed Phenotype Acute Leukemia\|Refractory Myelodysplastic Syndrome\|Refractory Acute Leukemia of Ambiguous Lineage\|Refractory Acute Undifferentiated Leukemia	December 3, 2020	Phase 1
NCT03250338	Arog Pharmaceuticals, Inc.	Relapsed+Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	June 5, 2018	Phase 3
NCT00562965	Pfizer\|UCB Pharma	Lymphoma, Follicular	November 2007	Phase 3
NCT02306291	GlycoMimetics Incorporated	Leukemia, Myeloid, Acute	March 2015	Phase 1\|Phase 2
NCT00119730	Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Biogen	Mantle Cell Lymphoma	February 2005	Phase 2
NCT01154439	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	October 2010	Phase 1
NCT00499018	Fondazione Italiana Linfomi ONLUS\|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte	Diffuse Large B-Cell Lymphoma\|IPI?2	January 2006	Phase 3
NCT04718376	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Platinum-resistant Ovarian Cancer	January 12, 2021	Phase 1
NCT04195945	Fred Hutchinson Cancer Center\|Jazz Pharmaceuticals	Acute Myeloid Leukemia\|Myeloid Neoplasm	March 11, 2020	Phase 2
NCT02043756	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Neoplasms	August 2011	Phase 1
NCT03531918	Fred Hutchinson Cancer Center\|Pfizer	Acute Myeloid Leukemia	September 14, 2018	Phase 1\|Phase 2
NCT01839240	University of Chicago\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	June 6, 2012	Phase 1
NCT04024241	Shenzhen People´s Hospital	Acute Myelogenous Leukemia\|Chemotherapy	September 1, 2017
NCT00107354	Fred Hutchinson Cancer Center	Leukemia\|Myelodysplastic Syndromes	December 1998	Phase 1
NCT02631252	Alison Sehgal, MD, MS\|University of Pittsburgh	Leukemia, Acute Myelogenous	August 18, 2016	Phase 1
NCT00002517	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	March 1993	Phase 3
NCT05173545	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Recurrent+Refractory Lymphoma	July 29, 2019	Phase 1
NCT01342887	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	April 2011	Phase 1\|Phase 2
NCT01700946	St. Jude Children´s Research Hospital\|Cookies for Kids´ Cancer\|Assisi Foundation	Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood B-Lymphoblastic Lymphoma	April 15, 2013	Phase 2
NCT00003232	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Pain\|Prostate Cancer\|Quality of Life	November 24, 1997	Phase 3
NCT03012672	University of Washington\|National Cancer Institute (NCI)	Acute Leukemia of Ambiguous Lineage\|Acute Myeloid Leukemia\|Myeloid Neoplasm	December 30, 2016	Phase 2
NCT00219908	Rennes University Hospital\|Bayer\|Wyeth is now a wholly owned subsidiary of Pfizer\|Farmades, Italy	Relapsing-Remitting Multiple Sclerosis	July 1999	Phase 2
NCT00151255	University of Ulm	Acute Myeloid Leukemia	June 2004	Phase 3
NCT00002719	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia\|Neutropenia	December 1995	Phase 3
NCT00317408	European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma\|National Cancer Institute (NCI)	Lymphoma	April 2004	Not Applicable
NCT02553460	St. Jude Children´s Research Hospital\|Gateway for Cancer Research\|Baylor College of Medicine	Acute Lymphoblastic Leukemia	January 29, 2016	Phase 1\|Phase 2
NCT00512252	Washington University School of Medicine	Leukemia, Myeloid, Acute	July 2007	Phase 1\|Phase 2
NCT01260714	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia\|Adult Acute Monoblastic Leukemia\|Adult Acute Monocytic Leukemia\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With Maturation\|Adult Acute Myeloid Leukemia With Minimal Differentiation\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Myeloid Leukemia Without Maturation\|Adult Acute Myelomonocytic Leukemia\|Adult Erythroleukemia\|Adult Pure Erythroid Leukemia\|Alkylating Agent-Related Acute Myeloid Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	December 2010	Phase 1
NCT02461537	DKMS gemeinnützige GmbH	Acute Myeloid Leukemia	September 17, 2015	Phase 3
NCT00052299	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	September 2002	Phase 3
NCT00003602	Riverside Haematology Group\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	March 1998	Phase 3
NCT05464433	Sun Yat-sen University	Extranodal Natural Killer T Cell Lymphoma	July 30, 2022	Phase 1\|Phase 2
NCT05100329	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Advanced Pancreatic Cancer	November 2021	Phase 2
NCT02520011	Sumitomo Pharma Oncology, Inc.	Acute Myeloid Leukemia	March 14, 2016	Phase 2
NCT00002688	University Medical Center Groningen\|National Cancer Institute (NCI)	Leukemia	February 1995	Phase 2
NCT04196010	University of Washington	Myeloid Neoplasm\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	May 8, 2020	Phase 1
NCT04778410	Gilead Sciences	Myeloid Malignancies	June 28, 2021	Phase 2
NCT00003068	University of Arizona\|National Cancer Institute (NCI)	Breast Cancer\|Drug+Agent Toxicity by Tissue+Organ	June 1997	Phase 2
NCT00002905	Centro di Riferimento Oncologico - Aviano\|National Cancer Institute (NCI)	Lymphoma	June 1995	Phase 2
NCT02686593	The University of Hong Kong	Acute Myeloid Leukemia	February 1, 2016	Phase 2
NCT03118466	Massachusetts General Hospital\|Celgene	AML	September 25, 2017	Phase 2
NCT00003728	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	December 1998	Phase 3
NCT00254410	M.D. Anderson Cancer Center\|OSI Pharmaceuticals\|Genentech, Inc.	Chronic Lymphocytic Leukemia	March 14, 2005	Phase 2
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00032149	Lymphoma Trials Office\|National Cancer Institute (NCI)	Lymphoma	October 2001	Phase 1\|Phase 2
NCT03504410	Cornerstone Pharmaceuticals	Relapsed+Refractory Acute Myeloid Leukemia	November 12, 2018	Phase 3
NCT02756572	University of Washington\|National Cancer Institute (NCI)	Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|Chronic Myelomonocytic Leukemia-2\|High Grade Malignant Neoplasm\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts-2\|Myeloid Neoplasm\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	September 22, 2016	Phase 2
NCT00146159	Wyeth is now a wholly owned subsidiary of Pfizer	Secondary Progressive Multiple Sclerosis	March 2005	Phase 3
NCT01483690	Therapeutic Advances in Childhood Leukemia Consortium	Acute Lymphoblastic Leukemia\|Precursor B-Cell Lymphoblastic Leukemia\|Precursor T-Cell Lymphoblastic Leukemia	December 2011	Phase 1\|Phase 2
NCT00853008	PETHEMA Foundation	Acute Lymphoblastic Leukemia	January 2003	Phase 4
NCT00274963	German CLL Study Group	Chronic Lymphocytic Leukemia	October 2004	Phase 2
NCT00143975	University of Ulm	Leukemia, Myeloid, Acute	June 2004	Phase 2
NCT00436839	Sanofi	Prostatic Neoplasms	January 2007	Phase 3
NCT04900766	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unresectable or Metastatic Bone and Soft Tissue Sarcoma	June 2021	Phase 1
NCT02688140	Technische Universität Dresden\|Gruppo Italiano Malattie EMatologiche dell´Adulto\|Groupe Francophone des Myelodysplasies\|HOVON - Dutch Haemato-Oncology Association\|Programa para el Tratamiento de Hemopatías Malignas\|German Federal Ministry of Education and Research\|Teva Pharmaceuticals Europe	Acute Promyelocytic Leukemia	June 2016	Phase 3
NCT00331344	National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer\|Stage IV Prostate Cancer	April 2006	Phase 1\|Phase 2
NCT05575973	Jianfeng Zhou\|CSPC Ouyi Pharmaceutical Co., Ltd.\|Huazhong University of Science and Technology	Diffuse Large B-cell Lymphoma	October 10, 2022	Phase 2
NCT00661492	US Oncology Research\|Eli Lilly and Company\|Oregon Health and Science University	Androgen-independent Prostate Cancer	May 2008	Phase 2
NCT00003215	Swiss Group for Clinical Cancer Research	Lymphoma	April 1997	Phase 3
NCT00003297	Georgetown University\|National Cancer Institute (NCI)	Ovarian Cancer	December 1997	Phase 1\|Phase 2
NCT01627938	PD Dr. Andrew Chan\|Ruhr University of Bochum	Multiple Sclerosis	April 2012	Phase 2
NCT01349972	National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	April 2011	Phase 2
NCT00882076	Milton S. Hershey Medical Center	Leukemia	March 2009	Phase 1
NCT00003650	UNICANCER	Lymphoma	February 1997	Phase 3
NCT00866918	Children´s Oncology Group\|National Cancer Institute (NCI)	Childhood Acute Promyelocytic Leukemia With PML-RARA\|Myeloid Neoplasm	March 9, 2009	Phase 3
NCT03839446	Konstantinos Lontos\|Pfizer\|University of Pittsburgh	Acute Myeloid Leukemia	February 28, 2019	Phase 2
NCT01904643	Stanford University\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	February 2014	Phase 1
NCT00005985	Masonic Cancer Center, University of Minnesota	Lymphoma	August 2000	Phase 2
NCT02021825	Xuanwu Hospital, Beijing	Neuromyelitis Optica\|Neuromyelitis Optica Spectrum Disorders	March 2009	Phase 4
NCT00005987	Masonic Cancer Center, University of Minnesota	Multiple Myeloma and Plasma Cell Neoplasm	August 2000	Phase 2
NCT04668690	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Peripheral T Cell Lymphoma	January 1, 2021	Phase 3
NCT05522192	Hui Zeng\|CSPC Ouyi Pharmaceutical Co., Ltd.\|First Affiliated Hospital of Jinan University	Relapsed or Refractory Acute Myeloid Leukemia	July 21, 2022	Phase 1\|Phase 2
NCT00002674	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Leukemia	October 1994	Phase 2
NCT00002805	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 1997	Phase 2
NCT00183989	University of Southern California	Mantle Cell Lymphoma	August 2000	Phase 2
NCT02339740	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Promyelocytic Leukemia With PML-RARA	June 29, 2015	Phase 3
NCT00634244	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	October 2008	Phase 2
NCT05527275	Sun Yat-sen University	Relapsed and Refractory Peripheral T-cell Lymphoma	October 1, 2022	Phase 1\|Phase 2
NCT00006045	Facet Biotech\|National Cancer Institute (NCI)	Leukemia	March 2000	Phase 3
NCT00005823	Leukemia Research Fund\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	December 1998	Phase 3
NCT01828489	Vastra Gotaland Region	Pediatric Acute Myeloblastic Leukemia	March 2013	Phase 3
NCT02200978	South China Children´s Leukemia Group	Childhood Acute Promyelocytic Leukemia	September 2011	Phase 4
NCT02523976	Institute of Hematology & Blood Diseases Hospital	Acute,Leukemia, Lymphoid	August 1, 2015	Phase 2
NCT05052970	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Relapsed or Refractory Multiple Myeloma	October 20, 2021	Phase 1
NCT00109837	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	April 2005	Phase 2
NCT01249430	National Cancer Institute (NCI)	Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	January 20, 2011	Phase 1
NCT03591510	Novartis Pharmaceuticals\|Novartis	FLT3-mutated Acute Myeloid Leukemia	March 13, 2019	Phase 2
NCT05458180	Tianjin Medical University Cancer Institute and Hospital\|CSPC Ouyi Pharmaceutical Co., Ltd.	Peripheral T-cell Lymphoma	July 7, 2022	Phase 1
NCT05495100	Second Affiliated Hospital, School of Medicine, Zhejiang University\|Ningbo No. 1 Hospital\|Jinhua Central Hospital\|Huizhou Municipal Central Hospital	Peripheral T Cell Lymphoma	August 11, 2022	Phase 2
NCT01830777	Massachusetts General Hospital	Acute Myelogenous Leukemia	May 2013	Phase 1
NCT00003407	Rush University Medical Center\|National Cancer Institute (NCI)	Drug+Agent Toxicity by Tissue+Organ\|Leukemia\|Myelodysplastic Syndromes\|Neutropenia	April 1998	Phase 2
NCT02044796	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	January 23, 2014	Phase 1\|Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 193.27 mM ; Need ultrasonic)

DMSO : ≥ 43 mg/mL ( 83.11 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9327 mL	9.6637 mL	19.3274 mL
5 mM	0.3865 mL	1.9327 mL	3.8655 mL
10 mM	0.1933 mL	0.9664 mL	1.9327 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
3.

Add each solvent one by one: PBS

Solubility: 2 mg/mL (3.87 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

* All of the co-solvents are available by MCE.

References

[1] Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.
[2] Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
[3] Venza I, et al. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013 Mar;26(2):193-204.
[4] Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.
[5] Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308.

Synonyms

9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, hydrochloride (1:2)

9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, dihydrochloride

CL 232315

Mitoxantrone hydrochloride

NSC 301739

DHAD

Novantrone

Mitoxantrone dihydrochloride

Bisantrone

Novatrone

Immunex

NCI 301739

Novantron

Mitoxantrone HCl

PW 3405

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart